JAK Inhibitor Therapy in the Myeloproliferative Neoplasm Population

Starting Therapy for Intermediate-Risk Myelofibrosis Based on Hemoglobin

During a live event, Mark J. Fesler, MD, and participants discussed selection and timing of initiation of JAK inhibitor therapy for myelofibrosis.

Considering Therapy in a Patient With Myelofibrosis Eligible for Transplant

During a live event, Mark J. Fesler, MD, and participants discuss next steps for a 68-year-old patient with intermediate-risk myelofibrosis.

Reevaluating Available Options for Anemia in Myelofibrosis

During a live event, Andrew Kuykendall, MD, discussed management of anemia before and during use of JAK inhibitor for myelofibrosis in the second of 2 articles.

Degree of Anemia Influences Therapy for Myelofibrosis

During a Case-Based Roundtable® event, Andrew Kuykendall, MD, and participants discussed the the importance of early intervention and consideration of anemia with JAK inhibitor therapy for patients with myelofibrosis in the first article of a 2-part series.

Connecting Spleen Volume Reduction to Survival Outcomes in MF

During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the correlation between spleen volume responses and survival outcomes for patients with myelofibrosis in the second article of a 2-part series.

Weighing the Triggers for Initiating JAK2 Inhibition Therapy in MF

During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the triggers physicians need to consider when deciding to initiate therapy for patients with myelofibrosis in the first article of a 2-part series.

JAK-STAT Pathway–Targeting Approaches in Myelofibrosis Are Evolving

During a Targeted Oncology™ Case-Based Roundtable™ event, Raajit K. Rampal, MD, gave an overview of the classification, risk assessment, and current therapy options for patients with myelofibrosis.

Management of Ruxolitinib in MF Allows for Continued Survival Benefit

In the second article of a 2-part series, Pankit Vachhani, MD, highlights the impact ruxolitinib has had, and continues, to have in treatment for patients with myelofibrosis and how physicians should manage this treatment for their patients.

Defining and Treating Classic Cases of Myeloproliferative Neoplasms

In the first article of a 2-part series, Pankit Vachhani, MD, discusses what makes classical cases of myeloproliferative neoplasms unique and how ruxolitinib impacts their reduction of spleen volume.

Current Approaches to Diagnose and Treat Primary Myelofibrosis

During a Targeted Oncology™ Case-Based Roundtable™ event, Rami Komrokji, MD, discussed elements to diagnosing myelofibrosis and how to approach risk stratification before treatment.

Ruxolitinib’s Role for Symptoms and Survival Benefit in Myelofibrosis

During a Targeted Oncology case-based roundtable event, Rami Komrokji, MD, discussed data supporting the use of ruxolitinib and what role it may play in improving long-term outcomes for patients with myelofibrosis. This is the second of 2 articles based on this event.

Initiating Therapy for Myelofibrosis Based on Risk Assessment

During a Targeted Oncology case-based roundtable event, Rami Komrokji, MD, and participants discussed when to start treatment for patients with myelofibrosis.

Risk Assessment and Treatment Approaches for Myelofibrosis

During a Targeted Oncology case-based roundtable event, Pankit Vachhani, MD, discussed with participants how to assess risk and begin treatment for myelofibrosis. This is the second of 2 articles based on this event.

Discussing the Diagnostic Process for Primary Myelofibrosis

During a Targeted Oncology case-based roundtable event, Pankit Vachhani, MD, discussed with participants how they would diagnose a patient who potentially has primary myelofibrosis.

Part 2: Maximizing Efficacy and Survival With Ruxolitinib for Myelofibrosis

During a live virtual event, Ruben Mesa, MD, discussed the clinical trials and challenges of using ruxolitinib for patients with myelofibrosis.

Part 1: Considering JAK Inhibitors and Stem Cell Transplant for Myelofibrosis

During a live virtual event, Ruben Mesa, MD, discussed the use and sequencing of JAK inhibitors and stem cell transplant for patients with myelofibrosis.